Mitochondria-Targeted Cassic Acid Base Nanoprodrug for Enhanced Anti-Inflammatory and Osteogenic Effects in Osteoarthritis.

ABSTRACT: CATPCS prodrug-based nanodrug delivery system (PNDDS), a mitochondria-targeted nanoprodrug combining Cassic acid (CA) with a PEG-modified chitosan-tripolyphosphate (TPP) molecule (CATPCS), overcomes the limitations of free Cassic acid in treating osteoarthritis (OA) and bone regeneration. FTIR and DLS confirm that lyophilized CATPCS self-assembles into stable, homogeneous spherical nanoparticles (230.8 ± 45.5 nm, PDI: 0.180, ζ potential: 30.5 ± 9.2 mV). For targeted delivery, HR-TEM scans verified this spherical morphology. In vitro studies show that IL-1β-stimulated chondrocytes internalize and colocalize CATPCS more effectively than free CA and CA NPs owing to the positively charged TPP moiety. CATPCS and CA NPs have in vitro cytotoxicity lower than that of free CA, indicating biocompati

SUBMITTER: Yu P 

PROVIDER: S-EPMC12368642 | biostudies-literature | 2025 Aug

REPOSITORIES: biostudies-literature